Patents Assigned to Boehringer Ingelheim Pharma GmbH & Co. KG
  • 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
    Patent number: 7119093
    Abstract: The present invention relates to the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycabonyl-2-indolinone-monoethanesulphonate of formula I and the use thereof as a pharmaceutical composition
    Type: Grant
    Filed: July 21, 2003
    Date of Patent: October 10, 2006
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Gerald J. Roth, Guenter Linz, Peter Sieger, Werner Rall, Frank Hilberg, Thomas Bock
  • COMPOUNDS FOR THE REDUCTION OF EXCESSIVE FOOD INTAKE
    Publication number: 20060223869
    Abstract: The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake.
    Type: Application
    Filed: June 26, 2006
    Publication date: October 5, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Michael PIEPER, Joachim Mierau
  • Benzoylguanidine salt and hydrates thereof
    Publication number: 20060217396
    Abstract: 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride and its hydrates, processes for preparing this benzoylguanidine salt and its hydrates, pharmaceutical compositions containing this benzoylguanidine salt and its hydrates, and its use in treating diseases, particularly those in which inhibition of the cellular Na+/H+ exchange is of therapeutic benefit.
    Type: Application
    Filed: June 1, 2006
    Publication date: September 28, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Christian Eickmeier, Peter Sieger, Werner Rall, Volkmar Koerner, Rolf Herter
  • Process for the manufacture of 4-(6-bromohexyloxy)-butylbenzene
    Patent number: 7112701
    Abstract: The present invention relates to an improved process for preparing 4-(6-bromohexyloxy)-butylbenzene by reacting 4-phenylbutanol with 1,6-dibromohexane in the presence of a base and a phase transfer catalyst, wherein 4-phenylbutanol in a diluent is metered into a mixture consisting of 1,6-dibromohexane, a base, a phase transfer catalyst and a diluent, and the use of the 4-(6-bromohexyloxy)-butylbenzene thus prepared for producing salmeterol in a method known per se.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: September 26, 2006
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Oliver Meyer, Helmut Heitger
  • Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
    Patent number: 7109192
    Abstract: The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula wherein R1 to R4 are defined as in claim 1, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: September 19, 2006
    Assignee: Boehringer Ingelheim Pharma GmbH & Co KG
    Inventors: Norbert Hauel, Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Roland Maier, Michael Mark, Mohammad Tadayyon, Iris Kauffmann-Hefner
  • Method for reducing the mortality rate
    Publication number: 20060205758
    Abstract: A method for reducing the mortality rate in a patient comprising administering to the patient a therapeutically effective amount of a tiotropium salt.
    Type: Application
    Filed: May 15, 2006
    Publication date: September 14, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Bernd Disse, Steven Kesten, Theodore Witek
  • Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
    Publication number: 20060205711
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: May 22, 2006
    Publication date: September 14, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Michael Mark, Matthias Eckhardt, Elke Langkopf, Roland Maier, Ralf Lotz
  • Bicyclic oligopeptides
    Patent number: 7101848
    Abstract: The invention relates to a bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, comprised of: (a) a first cyclic group, which comprises at least one cysteine group and is formed by an amide bonding of the N-terminal amino acid with the second carboxylate group of a diacid amino acid, and (b) a second cyclic group which is formed by an amide bonding of an amino acid with the ?-carboxylate group of said diacid amino acid, and by a disulfide bonding of the C-terminal cysteine and a cysteine group within the first cyclic group (a); and to the use of such bicyclic oligopeptides for the preparation of a medicament for the treatment or prevention of diseases, in which glucagon receptors are involved.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: September 5, 2006
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Olivier Potterat, Ruediger Streicher, Klaus Wagner, Till Maurer, Juergen Mack, Stefan Peters
  • Pharmaceutical composition for intranasal administration containing a CGRP antagonist
    Publication number: 20060193786
    Abstract: The invention relates to pharmaceutical compositions for nasal application, comprising selected CGRP antagonists which are described in WO 98/11128, as well as a process for the preparation thereof.
    Type: Application
    Filed: May 19, 2006
    Publication date: August 31, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Bernd Kruss, Ulrich Busch, Klaus Jost, Marc Gaiser
  • Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
    Publication number: 20060194813
    Abstract: The present invention relates to indolinone derivatives substituted in the 6 position of general formula wherein R1 to R6 and X are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof, which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
    Type: Application
    Filed: July 22, 2003
    Publication date: August 31, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Armin Heckel, Frank Hilberg, Thorsten Lehmann-Lintz, Guenter Linz, Joerg Kley, Jacobus Van Meel, Werner Rall, Gerald Roth, Peter Sieger, Ulrike Tontsch-Grunt
  • Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
    Patent number: 7094788
    Abstract: The present invention relates to new compounds of general formula 1 wherein X? and the groups A, B, R, R1, R2, R3, R3?, R4, R4?, Rx and Rx? may have the meanings given in the claims and in the specification, processes for preparing them and their use as pharmaceutical compositions.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: August 22, 2006
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Matthias Grauert, Michael P. Pieper, Gerald Pohl, Georg Speck, Steffen Breitfelder
  • ADMINISTRATION FORM FOR THE ORAL APPLICATION OF 3-[(2-{[4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO]-METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)-PYRIDIN-2-YL-AMINO]-PROPIONIC ACID ETHYL ESTER AND THE SALTS THEREOF
    Publication number: 20060183779
    Abstract: The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof.
    Type: Application
    Filed: May 5, 2006
    Publication date: August 17, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co., KG
    Inventors: Ulrich Brauns, Norbert Hauel
  • Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
    Publication number: 20060183693
    Abstract: A method of treatment or prevention of headache, migraine or cluster headaches, which method comprises co-administration of a therapeutically effective amount of the compound 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096BS] or a physiologically acceptable salt thereof and a therapeutically effective amount of a second active antimigraine drug, particularly sumatriptan, zolmitriptan or dihydroergotamin or a physiologically acceptable salt thereof, as well as to the corresponding pharmaceutical compositions and the preparation thereof.
    Type: Application
    Filed: March 7, 2006
    Publication date: August 17, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Henri Doods, Wolfgang Eberlein, Klaus Rudolf
  • Process for Preparation of Isochroman and Derivatives Thereof
    Publication number: 20060173196
    Abstract: The present invention relates to an improved process for preparing compounds of formula 1 on an industrial scale, wherein R1, R2 and R3 are independently C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl or aryl; and R4 is H, OC1-6-alkyl, Oaryl, OH, C1-6-alkyl, halogen, CN or NO2.
    Type: Application
    Filed: January 26, 2006
    Publication date: August 3, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Ralf Lock
  • New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
    Publication number: 20060173061
    Abstract: The present invention relates to new beta-agonists of general formula 1: wherein the groups R1 to R12 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these compounds and their use as pharmaceutical compositions.
    Type: Application
    Filed: March 9, 2006
    Publication date: August 3, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Thomas Trieselmann, Bradford Hamilton, Dirk Stenkamp, Stephan Mueller
  • Arylglycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds
    Patent number: 7084140
    Abstract: The invention relates to new arylglycinamide derivatives of general formula I and the pharmaceutically acceptable salts thereof, wherein R1 and R2 together with the N to which they are bound form a ring of the formula in which R3, R4, R5, Ar, R6, R7, R8, R9, R10, R11, r, s and t have the meanings given in the specification and the preparation and use thereof. The new compounds are valuable neurokinin (tachykinin) antagonists.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: August 1, 2006
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Franz Esser, Gerd Schnorrenberg, Kurt Schromm, Horst Dollinger, Birgit Jung, Georg Speck
  • Medicaments comprising steroids and a novel anticholinergic
    Patent number: 7084153
    Abstract: A pharmaceutical composition comprising: (a) a salt of formula 1 ?wherein: X? is an anion with a single negative charge; and (b) a steroid 2, processes for preparing such pharmaceutical composition, and their use in the treatment of respiratory complaints.
    Type: Grant
    Filed: March 19, 2003
    Date of Patent: August 1, 2006
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rolf Banholzer, Helmut Meissner, Gerd Morschhaeuser, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Christopher John Montague Meade, Michel Pairet
  • Method of Using Flibanserin for Neuroprotection
    Publication number: 20060160822
    Abstract: The present invention relates to the use of 1-[2-(4-(3-trifluoromethyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one, optionally in the form of its pharmaceutically acceptable acid addition salts and optionally in the form of its hydrates or solvates, for preparing a pharmaceutical composition with a neuroprotective activity.
    Type: Application
    Filed: April 4, 2006
    Publication date: July 20, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Franco BORSINI
  • Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
    Publication number: 20060154976
    Abstract: A method of treatment of indications which can be positively influenced by inhibition of AT1 mediated effects with maintenance of AT2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death, or of indications associated with the increase of AT1 receptors in the subepithelial area or increase of AT2 receptors in the epithelia, comprising coadministration of effective amounts of an angiotensin II antagonist and an ACE inhibitor, pharmaceutical compositions containing an angiotensin II antagonist together with an ACE inhibitor and the use of an angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.
    Type: Application
    Filed: March 15, 2006
    Publication date: July 13, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH and Co. KG
    Inventors: Peter Boehm, Wolf Meinicke, Axel Riedel
  • Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
    Patent number: 7064130
    Abstract: A method of treatment of the human or non-human animal body for treating NO-dependent microcirculation disorders is disclosed, for example microcirculation disorders caused by metabolic diseases, such as elevated levels of homocystin-homocystein inflammatory reactions or autoimmune diseases, furthermore peripheral microcirculation disorders or microcirculation disorders associated with increased cell fragmentation, which method comprises administering to a human or non-human animal body in need of such treatment an effective amount of a pharmaceutical composition containing a substance which scavenges free radicals, e.g. a pyrimido-pyrimidine selected from Dipyridamole, Mopidamol and the pharmaceutically acceptable salts thereof, and the use such substance for the manufacture of a corresponding pharmaceutical composition, optionally in combination with an agent capable of increasing NO procution.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: June 20, 2006
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Wolfgang Eisert